Kangstem Biotech Co. Ltd (217730.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea · ISIN KR7217730001

Price
1,876.00 KRW
Market cap
176.45 bn KRW
P/E (2025)
–
P/S (2025)
49.39
Dividend yield
0.00 %
Net margin
-293.41 %
Return on equity (ROE)
-15.27 %
Return on assets (ROA)
-12.86 %

Kangstem Biotech Co. Ltd financials

Fiscal year20242025
Revenue7.75 bn KRW3.57 bn KRW
Gross profit4.33 bn KRW845.01 m KRW
Operating income-14.74 bn KRW-17.67 bn KRW
EBIT-6.66 bn KRW-9.97 bn KRW
Net income-7.67 bn KRW-10.48 bn KRW
Diluted EPS – continuing operations-117.06 KRW-111.45 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Kangstem Biotech Co. Ltd

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.